Results 51 to 60 of about 138,238 (309)
Association of Disease Location and Treatment With Survival in Diffuse Large B-Cell Lymphoma of the Eye and Ocular Adnexal Region. [PDF]
, 2017 Importance: Primary diffuse large B-cell lymphoma (DLBCL) of the ocular region is rare, and the utility of surgery and radiation therapy remains unresolved.
Ahmed, Aseef H H. +2 more
core +2 more sources
Advanced Science, EarlyView.An autologous whole‐tumor‐cell vaccine (rWTC‐MBTA) is evaluated in murine CNS lymphoma. Subcutaneous vaccination activates dendritic cells, broadens T‐cell priming, and drives lymphocyte trafficking to brain tumors, producing durable tumor control. Longitudinal bioluminescence and adoptive‐transfer assays verify CNS engagement. Combination with anti‐PD‐
Yaping Zhang +10 more
wiley +1 more source
Cerebral type MALT non Hodgkin lymphoma
Revista Cubana de Medicina Militar, 2021 Introduction: Non-Hodgkin's lymphomas generally have their origin in the lymphoid system, there is a great diversity of them, which makes their classification and definitive pathological diagnosis difficult.
Yaimara Zunen Hernández Puentes +3 more
doaj
Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. [PDF]
, 2015 Immunologic checkpoint blockade with antibodies against the programmed cell death protein-1 (PD-1) or its ligand (PD-L1) is an effective method for reversing cancer immunosuppression and thereby promoting immune responses against several cancer types ...
Homet Moreno, B, Ribas, A
core +2 more sources
Advanced Science, EarlyView.Osteosarcoma is the most common primary bone tumor with limited treatment options and a terrible prognosis. This review provides a comprehensive summary of the recent development of osteoimmunomodulatory implants for post‐operative osteosarcoma treatment, of which the potential utility in evoking durable anti‐osteosarcoma immunity and accelerating bone
Yilong Dong +6 more
wiley +1 more source
CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma
Haematologica, 2018 Chemotherapy and hematopoietic stem cell transplantation are effective treatments for most Hodgkin lymphoma patients, however there remains a need for better tumor-specific target therapy in Hodgkin lymphoma patients with refractory or relapsed disease ...
Ziduo Li +21 more
doaj +1 more source
Extranodal non-Hodgkin's lymphoma [PDF]
Cancer, 1980 From 1964 to 1977, 42 patients with Stages I and II non-Hodgkin's lymphoma involving the extranodal sites were seen and treated with curative intent by radiotherapy in the Department of Therapeutic Radiology at Rush-Presbyterian-St. Luke's Medical Center.
S, Reddy +3 more
openaire +2 more sources
GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy
Advanced Science, EarlyView.Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu +11 more
wiley +1 more source
Haematologica, 2018 Inflammation and B-cell hyperactivation have been associated with non-Hodgkin lymphoma development. This prospective analysis aimed to further elucidate pre-diagnosis plasma immune marker profiles associated with non-Hodgkin lymphoma risk.
Mara M. Epstein +11 more
doaj +1 more source
T-Cell/Histiocyte Rich Large B-Cell Lymphoma –A Case Series with Review of Literature [PDF]
National Journal of Laboratory Medicine, 2017 T-Cell/Histiocyte Rich Large B-Cell Lymphoma (THRLBCL) is a rare variant of Diffuse Large B Cell Lymphoma (DLBCL). This entity differs from the classical DLBCL in the morphology as well as immunohistochemical expression of various CD markers.
Priavadhana Rajan Prasaad +1 more
doaj +1 more source